相似文献
1
The price of whole-genome sequencing may be decreasing, but who will be sequenced?全基因组测序的价格可能在下降，但谁会接受测序呢？
Per Med. 2017 May;14(3):203-211. doi: 10.2217/pme-2016-0075. Epub 2017 May 23.
2
Willingness to pay for the maintenance of equity in a local ivermectin distribution scheme in Toro, Northern Nigeria.为维持尼日利亚北部托罗地区伊维菌素地方分配计划的公平性而支付的意愿。
Public Health. 1999 Jul;113(4):193-4.
3
Factors affecting the willingness to pay for implants: A study of patients in Riyadh, Saudi Arabia.影响植入物支付意愿的因素：沙特阿拉伯利雅得患者的一项研究。
Dent Res J (Isfahan). 2012 Nov;9(6):719-24.
4
Willingness to pay for social health insurance among informal sector workers in Wuhan, China: a contingent valuation study.中国武汉非正规部门劳动者对社会医疗保险的支付意愿：一项意愿调查评估研究
BMC Health Serv Res. 2007 Jul 20;7:114. doi: 10.1186/1472-6963-7-114.
5
Public attitudes in Japan toward participation in whole genome sequencing studies.日本人对参与全基因组测序研究的态度。
Hum Genomics. 2018 Apr 13;12(1):21. doi: 10.1186/s40246-018-0153-7.
6
Willingness-to-pay for community-based insurance in Burkina Faso.布基纳法索基于社区的保险的支付意愿。
Health Econ. 2003 Oct;12(10):849-62. doi: 10.1002/hec.771.
7
Identifying factors that affect patients' willingness to pay for inhaled insulin.确定影响患者购买吸入式胰岛素意愿的因素。
Res Social Adm Pharm. 2009 Sep;5(3):253-61. doi: 10.1016/j.sapharm.2008.10.001. Epub 2009 Jan 21.
8
Patient preferences for depression treatment programs and willingness to pay for treatment.患者对抑郁症治疗方案的偏好及治疗支付意愿。
J Ment Health Policy Econ. 2007 Jun;10(2):73-85.
9
Willingness to pay for community-based health insurance in Nigeria: do economic status and place of residence matter?尼日利亚对社区医疗保险的支付意愿：经济状况和居住地重要吗？
Health Policy Plan. 2010 Mar;25(2):155-61. doi: 10.1093/heapol/czp046. Epub 2009 Oct 26.
10
Willingness to pay for health improvements of physical activity on prescription.对处方开具的体力活动促进健康的改善支付意愿。
Scand J Public Health. 2010 Mar;38(2):151-9. doi: 10.1177/1403494809357099. Epub 2010 Jan 11.
引用本文的文献
1
The current stage of Italy in the implementation of genomics into the National Healthcare System: an application of the B1MG maturity level model.意大利在将基因组学应用于国家医疗保健系统方面的当前阶段：B1MG成熟度水平模型的应用
Front Public Health. 2025 Apr 16;13:1425990. doi: 10.3389/fpubh.2025.1425990. eCollection 2025.
2
Calibrating epigenetic clocks with training data error.用训练数据误差校准表观遗传时钟。
Evol Appl. 2023 Jul 26;16(8):1496-1502. doi: 10.1111/eva.13582. eCollection 2023 Aug.
3
EARLY CONSIDERATIONS OF GENETICS IN APHASIA REHABILITATION: A NARRATIVE REVIEW.失语症康复中遗传学的早期思考：一项叙述性综述
Aphasiology. 2023;37(6):835-853. doi: 10.1080/02687038.2022.2043234. Epub 2022 Feb 25.
4
ShareDNA: a smartphone app to facilitate family communication of genetic results.ShareDNA：一款帮助家庭成员间交流基因检测结果的智能手机应用程序。
BMC Med Genomics. 2021 Jan 6;14(1):10. doi: 10.1186/s12920-020-00864-0.
5
Metatranscriptomic Analysis Reveals Active Bacterial Communities in Diabetic Foot Infections.宏转录组分析揭示糖尿病足感染中活跃的细菌群落。
Front Microbiol. 2020 Jul 22;11:1688. doi: 10.3389/fmicb.2020.01688. eCollection 2020.
6
Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.弥合个性化医疗价值评估中的差距：对跨利益相关者和科学学科的结果指标需求的综述
Public Health Genomics. 2019;22(1-2):16-24. doi: 10.1159/000501974. Epub 2019 Aug 27.
本文引用的文献
1
What are people willing to pay for whole-genome sequencing information, and who decides what they receive?人们愿意为全基因组测序信息支付多少钱，又由谁来决定他们能得到什么信息呢？
Genet Med. 2016 Dec;18(12):1295-1302. doi: 10.1038/gim.2016.61. Epub 2016 Jun 2.
2
Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment.临床基因组测序中偶然发现结果反馈的社会偏好：一项离散选择实验
CMAJ. 2015 Apr 7;187(6):E190-E197. doi: 10.1503/cmaj.140697. Epub 2015 Mar 9.
3
Insurance companies are slow to cover next-generation sequencing.保险公司在承保下一代测序方面行动迟缓。
Nat Med. 2015 Mar;21(3):204-5. doi: 10.1038/nm0315-204.
4
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.消费者对个性化医疗的熟悉程度、看法及预期价值，重点关注肿瘤学中的应用。
Per Med. 2015 Jan 1;12(1):13-22. doi: 10.2217/pme.14.74.
5
Diagnostic clinical genome and exome sequencing.诊断性临床基因组和外显子组测序
N Engl J Med. 2014 Jun 19;370(25):2418-25. doi: 10.1056/NEJMra1312543.
6
Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.癌症患者对药物基因组检测的接受度、理解程度和支付意愿。
Pharmacogenet Genomics. 2014 Jul;24(7):348-55. doi: 10.1097/FPC.0000000000000061.
7
The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine.MedSeq 项目：将全基因组测序整合到临床医学中的一项随机试验。
Trials. 2014 Mar 20;15:85. doi: 10.1186/1745-6215-15-85.
8
Clinical interpretation and implications of whole-genome sequencing.全基因组测序的临床解读及意义。
JAMA. 2014 Mar 12;311(10):1035-45. doi: 10.1001/jama.2014.1717.
9
A systematic review of the factors associated with interest in predictive genetic testing for obesity, type II diabetes and heart disease.对与肥胖、II型糖尿病和心脏病预测性基因检测兴趣相关因素的系统评价。
J Hum Nutr Diet. 2014 Oct;27(5):479-88. doi: 10.1111/jhn.12179. Epub 2013 Nov 14.
10
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).基因组检测以确定药物反应：使用离散选择实验（DCE）衡量公众和患者的偏好。
BMC Health Serv Res. 2013 Oct 31;13:454. doi: 10.1186/1472-6963-13-454.
Zotero 插件